integral membrane protein 2BGenealiases: ABRI · BRI · BRI2 · BRICD2B · E25B · E3-16
Q-omics provides the consensus-scored ITM2B profile across patient tissues and cancer cell-line models. ITM2B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ITM2B is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, ITM2B protein abundance shows 26,416 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KICH, and GBM as cancer lineages where ITM2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ITM2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ITM2B survival associations across molecular data types. ITM2B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ITM2B RNA expression–survival associations across cancer types. High ITM2B expression shows unfavorable associations in STAD, but favorable associations in KIRC, MESO, SKCM, THCA and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ITM2B RNA expression.
This table summarizes ITM2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 10. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ITM2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ITM2B shows lower tumor expression in KICH, LUAD, BLCA, THCA, UCEC and LUSC. The KICH box plot shows higher ITM2B RNA expression in normal versus tumor tissue (log2 FC = −2.238, t-test p < 0.001).
This table shows molecular features associated with ITM2B in patient tissues and cancer cell lines. In patient samples, ITM2B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ITM2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LIVER and CNS.
